|
1
|
Dent R, Trudeau M, Pritchard KI, Hanna WM,
Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P and Narod SA:
Triple-negative breast cancer: Clinical features and patterns of
recurrence. Clin Cancer Res. 13:4429–4434. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kassam F, Enright K, Dent R, Dranitsaris
G, Myers J, Flynn C, Fralick M, Kumar R and Clemons M: Survival
outcomes for patients with metastatic triple-negative breast
cancer: Implications for clinical practice and trial design. Clin
Breast Cancer. 9:29–33. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jordan MA and Wilson L: Microtubules as a
target for anticancer drugs. Nat Rev Cancer. 4:253–265. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dumontet C and Jordan MA:
Microtubule-binding agents: A dynamic field of cancer therapeutics.
Nat Rev Drug Discov. 9:790–803. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Parker A, Kavallaris M and McCarroll JA:
Microtubules and their role in cellular stress in cancer. Front
Oncol. 4:1532014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bosch A, Eroles P, Zaragoza R, Viña JR and
Lluch A: Triple-negative breast cancer: Molecular features,
pathogenesis, treatment and current lines of research. Cancer Treat
Rev. 36:206–215. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yu KD, Zhu R, Zhan M, Rodriguez AA, Yang
W, Wong S, Makris A, Lehmann BD, Chen X, Mayer I, et al:
Identification of prognosis-relevant subgroups in patients with
chemoresistant triple-negative breast cancer. Clin Cancer Res.
19:2723–2733. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ullah MF: Cancer multidrug resistance
(MDR): A major impediment to effective chemotherapy. Asian Pac J
Cancer Prev. 9:1–6. 2008.PubMed/NCBI
|
|
9
|
Hasanabady MH and Kalalinia F: ABCG2
inhibition as a therapeutic approach for overcoming multidrug
resistance in cancer. J Biosci. 41:313–324. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–428. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ohga T, Uchiumi T, Makino Y, Koike K, Wada
M, Kuwano M and Kohno K: Direct involvement of the Y-box binding
protein YB-1 in genotoxic stress-induced activation of the human
multidrug resistance 1 gene. J Biol Chem. 273:5997–6000. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Holmes FA, Walters RS, Theriault RL,
Forman AD, Newton LK, Raber MN, Buzdar AU, Frye DK and Hortobagyi
GN: Phase II trial of taxol, an active drug in the treatment of
metastatic breast cancer. J Natl Cancer Inst. 83:1797–1805. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Brown T, Havlin K, Weiss G, Cagnola J,
Koeller J, Kuhn J, Rizzo J, Craig J, Phillips J and Von Hoff D: A
phase I trial of taxol given by a 6-hour intravenous infusion. J
Clin Oncol. 9:1261–1267. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
McGuire WP, Rowinsky EK, Rosenshein NB,
Grumbine FC, Ettinger DS, Armstrong DK and Donehower RC: Taxol: A
unique antineoplastic agent with significant activity in advanced
ovarian epithelial neoplasms. Ann Intern Med. 111:273–279. 1989.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fuchs DA and Johnson RK: Cytologic
evidence that taxol, an antineoplastic agent from Taxus brevifolia,
acts as a mitotic spindle poison. Cancer Treat Rep. 62:1219–1222.
1978.PubMed/NCBI
|
|
16
|
Schiff PB, Fant J and Horwitz SB:
Promotion of microtubule assembly in vitro by taxol. Nature.
277:665–667. 1979. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Haldar S, Jena N and Croce CM:
Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci USA.
92:4507–4511. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Weaver BA: How Taxol/paclitaxel kills
cancer cells. Mol Biol Cell. 25:2677–2681. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Guo B, Villeneuve DJ, Hembruff SL, Kirwan
AF, Blais DE, Bonin M and Parissenti AM: Cross-resistance studies
of isogenic drug-resistant breast tumor cell lines support recent
clinical evidence suggesting that sensitivity to paclitaxel may be
strongly compromised by prior doxorubicin exposure. Breast Cancer
Res Treat. 85:31–51. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
McDonald SL, Stevenson DA, Moir SE,
Hutcheon AW, Haites NE, Heys SD and Schofield AC: Genomic changes
identified by comparative genomic hybridization in
docetaxel-resistant breast cancer cell lines. Eur J Cancer.
41:1086–1094. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sharom FJ: ABC multidrug transporters:
Structure, function and role in chemoresistance. Pharmacogenomics.
9:105–127. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kim KY, Kim SH, Yu SN, Park SK, Choi HD,
Yu HS, Ji JH, Seo YK and Ahn SC: Salinomycin enhances
doxorubicin-induced cytotoxicity in multidrug resistant MCF-7/MDR
human breast cancer cells via decreased efflux of doxorubicin. Mol
Med Rep. 12:1898–1904. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kröger N, Achterrath W, Hegewisch-Becker
S, Mross K and Zander AR: Current options in treatment of
anthracycline-resistant breast cancer. Cancer Treat Rev.
25:279–291. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yonemori K, Katsumata N, Uno H, Matsumoto
K, Kouno T, Tokunaga S, Yamanaka Y, Shimizu C, Ando M, Takeuchi M
and Fujiwara Y: Efficacy of weekly paclitaxel in patients with
docetaxel-resistant metastatic breast cancer. Breast Cancer Res
Treat. 89:237–241. 2005. View Article : Google Scholar : PubMed/NCBI
|
